Cantel Medical (NYSE:CMD) and Axonics Modulation Technologies (NASDAQ:AXNX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.
This is a breakdown of recent recommendations for Cantel Medical and Axonics Modulation Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axonics Modulation Technologies||0||0||4||0||3.00|
Cantel Medical presently has a consensus target price of $114.00, indicating a potential upside of 67.03%. Axonics Modulation Technologies has a consensus target price of $21.48, indicating a potential upside of 3.27%. Given Cantel Medical’s higher possible upside, equities analysts plainly believe Cantel Medical is more favorable than Axonics Modulation Technologies.
This table compares Cantel Medical and Axonics Modulation Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axonics Modulation Technologies||N/A||N/A||N/A|
Cantel Medical pays an annual dividend of $0.20 per share and has a dividend yield of 0.3%. Axonics Modulation Technologies does not pay a dividend. Cantel Medical pays out 8.0% of its earnings in the form of a dividend.
Earnings and Valuation
This table compares Cantel Medical and Axonics Modulation Technologies’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cantel Medical||$871.92 million||3.27||$91.04 million||$2.51||27.19|
|Axonics Modulation Technologies||$710,000.00||815.59||-$32.48 million||($4.64)||-4.48|
Cantel Medical has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
86.0% of Cantel Medical shares are held by institutional investors. Comparatively, 31.9% of Axonics Modulation Technologies shares are held by institutional investors. 11.7% of Cantel Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cantel Medical beats Axonics Modulation Technologies on 11 of the 15 factors compared between the two stocks.
About Cantel Medical
Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Endoscopy segment offers automated endoscope reprocessing systems; infectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets, transport systems, and mobile medical carts; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Water Purification and Filtration segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratory and pharmaceutical, food and beverage, and commercial industrial customers. The company's Healthcare Disposables segment offers biological indicators, chemical integrators, sterilization pouches, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, amalgam separators, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.
About Axonics Modulation Technologies
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.